Biophytis S.A.
Clinical-stage biotech developing therapeutics for age-related degenerative diseases.
ALBPS | PA
Overview
Corporate Details
- ISIN(s):
- FR0012816825 (+4 more)
- LEI:
- 9695008GIE061NBGU106
- Country:
- France
- Address:
- 14 AVENUE DE L'OPERA, 75001 PARIS
- Website:
- https://www.biophytis.com/en/
Description
Biophytis S.A. is a clinical-stage biotechnology company focused on developing therapeutics to slow degenerative processes associated with aging and improve longevity. The company's primary strategy is centered on treating diseases that impair mobility. Its lead drug candidate, BIO101, is being advanced in late-stage clinical development for multiple age-related conditions. A key program is the SARA Phase 3 trial, the first-ever pivotal study for the treatment of sarcopenia (age-related muscle loss). Additionally, BIO101 is being evaluated in the OBA Phase 2 clinical trial for addressing muscle wasting in patients with obesity. The company aims to preserve muscle function and enhance functional outcomes for patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2018-05-24 18:00 |
BIOPHYTIS: Inclusion of the first patient in Phase 2b Study in Sarcopenia
|
English | 267.8 KB | ||
| 2018-05-16 20:26 |
Results of the 2018 Annual Meeting of Shareholders
|
English | 300.0 KB | ||
| 2018-05-16 20:26 |
Résultats de l’Assemblée Générale 2018
|
French | 263.8 KB | ||
| 2018-05-15 20:28 |
Biophytis obtient le statut de Médicament Orphelin aux Etats-Unis pour Sarconeo…
|
French | 243.8 KB | ||
| 2018-05-15 20:28 |
Biophytis receives Orphan Drug Designation from the FDA for Sarconeos in Duchen…
|
English | 243.1 KB | ||
| 2018-04-27 18:00 |
BIOPHYTIS fait le point sur le développement clinique de Macuneos et présente …
|
French | 329.5 KB | ||
| 2018-04-27 18:00 |
BIOPHYTIS updates on clinical development of Macuneos and presents its effects…
|
English | 338.9 KB | ||
| 2018-04-27 08:00 |
BIOPHYTIS : mise à disposition du Rapport financier 2017
|
French | 232.8 KB | ||
| 2018-04-27 08:00 |
BIOPHYTIS: 2017 Annual Financial Report made available
|
English | 226.7 KB | ||
| 2018-03-28 09:00 |
BIOPHYTIS : Résultats Annuels 2017
|
French | 357.8 KB | ||
| 2018-03-28 09:00 |
BIOPHYTIS : 2017 Full Year Results
|
English | 375.7 KB | ||
| 2018-03-20 18:58 |
Biophytis dépose une demande de désignation de Médicament Orphelin pour Sarcone…
|
French | 264.3 KB | ||
| 2018-03-20 18:58 |
Biophytis files for Orphan Drug Designation for Sarconeos in Duchenne Muscular …
|
English | 256.6 KB | ||
| 2018-03-01 07:45 |
Biophytis fait un point sur l’étude clinique SARA de Sarconeos dans la sarcopén…
|
French | 953.8 KB | ||
| 2018-03-01 07:45 |
Biophytis updates on SARA clinical study of Sarconeos in sarcopenia and present…
|
English | 938.8 KB |
Automate Your Workflow. Get a real-time feed of all Biophytis S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Biophytis S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Biophytis S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-11-22 | N/A | Other | Buy | 8,443,190 | 79,365.99 EUR |
| 2020-12-16 | N/A | Other | Sell | 500,000 | 499,000.00 EUR |
| 2020-12-16 | N/A | Other | Other | 313,417 | N/A |
| 2020-04-30 | N/A | Other | Other | 2,955,701 | 177,342.06 EUR |
Peer Companies
